Inventor · disambiguated record
Dennis Kirchhoff
Also filed as: KIRCHHOFF DENNIS
9 granted patents·7 pending applications·26 citations·filing 2016–2023
84Inventor score
Top patents by PatentIndex Score
16 records- 0195US11478554B2Antibody drug conjugates (ADCS) having enzymatically cleavable groupsBayer Pharma AG·Filed 2021·Granted Oct 25, 2022·5 cites·20 claims
- 0292US11643469B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2022·Granted May 9, 2023·1 cites·15 claims
- 0392US10744205B2Antibody drug conjugates of kinesin spindel protein (KSP) inhibitors with anti-CD123-antibodiesBayer Pharma AG·Filed 2016·Granted Aug 18, 2020·9 cites·28 claims
- 0491US11660351B2Antibody drug conjugates (ADCs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2017·Granted May 30, 2023·5 cites·50 claims
- 0590US11001636B2Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodiesBayer Pharma AG·Filed 2017·Granted May 11, 2021·5 cites·15 claims
- 0688US11998539B2Substituted aminoquinolones as DGKalpha inhibitors for immune activationBAYER AG·Filed 2022·Granted Jun 4, 2024·1 cites·24 claims
- 0781US2023399411A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2023·Application pending·0 cites
- 0875US11964953B2Substituted aminothiazoles as DGKzeta inhibitors for immune activationBAYER AG·Filed 2022·Granted Apr 23, 2024·0 cites·26 claims
- 0975US2023338559A1Antibody drug conjugates (adcs) having enzymatically cleavable groupsBayer Pharma AG·Filed 2023·Application pending·0 cites
- 1071US2021230284A1Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodiesBayer Pharma AG·Filed 2021·Application pending·0 cites
- 1165US2022362392A1Specific antibody drug conjugates (adcs) having ksp inhibitorsBayer Pharma AG·Filed 2022·Application pending·0 cites
- 1262US2023167078A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 1361US11433140B2Specific antibody drug conjugates (ADCs) having KSP inhibitorsBayer Pharma AG·Filed 2017·Granted Sep 6, 2022·0 cites·9 claims
- 1460US2023167103A1Substituted aminothiazoles as dgkzeta inhibitors for immune activationBAYER AG·Filed 2021·Application pending·0 cites
- 1557US12478621B2Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Granted Nov 25, 2025·0 cites·17 claims
- 1650US2023064809A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →